Invivyd shares rise as FDA approves late-stage trial design for COVID-19 therapy.

Invivyd's stock rose around 5% in pre-market trading after the FDA agreed with the company's late-stage trial design for its COVID-19 therapy, VYD2311. The LIBERTY Phase 3 clinical trial aims to evaluate the potential preventative option for COVID-19.